News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Provectus Pharmaceuticals Inc. Release: PV-10's Systemic Tumor-Specific Immune Response is Subject of Research Article Published in PLOS ONE



7/25/2013 9:57:38 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that an article based on research conducted at the Moffitt Cancer Center with intralesional PV-10 has been published in PLOS ONE, an international, peer-reviewed, open-access, online publication. The article, entitled, “Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer,” was authored by Paul Toomey, M.D., Krithika Kodumudi, Ph.D., Amy Weber, Lisa Kuhn, Ellen Moore, Arnod A. Sarnaik, M.D. and Shari Pilon-Thomas, Ph.D., all researchers with Moffitt’s Immunology Program. The featured work resulted in part from a Provectus-sponsored research program led by Pilon-Thomas.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES